Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 200 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Photon Emission Computed Tomography (SPECT) Clear all
Completed Not applicable Interventional Results available

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT02492867
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, V/Q SPECT, Durvalumab
Radiation · Drug · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 13, 2026, 2:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

NCT00612872
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease, Healthy Controls, Multiple Sclerosis
Interventions
[123I]CLINDE
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 13, 2026, 2:46 PM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT01313572
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

NCT01572701
View directory record Official record
Conditions
Prostate Cancer
Interventions
99mTc-MIP-1404
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Early Phase 1 Interventional

Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer

NCT00743314
View directory record Official record
Conditions
Breast Cancer, Lymphedema
Interventions
screening questionnaire administration, computed tomography, lymphoscintigraphy, single photon emission computed tomography, intensity-modulated radiation therapy, technetium Tc 99m sulfur colloid
Other · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 13, 2026, 2:46 PM EDT
Suspended Phase 2 Interventional

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

NCT06200103
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Clinical Observation, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 13, 2026, 2:46 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

NCT01264861
View directory record Official record
Conditions
Parkinson Disease
Interventions
Safinamide
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families

NCT00273351
View directory record Official record
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
[123I]B-CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 13, 2026, 2:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients

NCT00427674
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I] mZINT injection and serial dynamic SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies

NCT03456908
View directory record Official record
Conditions
Myeloma Before MV-NIS Treatment, Endometrial Cancer Before VSV-hINF-NIS Treatment
Interventions
18F-TFB-PET
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

NCT01141023
View directory record Official record
Conditions
Parkinson Disease
Interventions
DaTscan
Drug
Lead sponsor
Ken Marek, MD
Other
Eligibility
30 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
21
States / cities
Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

NCT01490723
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging, 90Y IbritumomabTiuxetan, Fludarabine, Bendamustine, Thymoglobulin, Tacrolimus, Methotrexate, Mycophenolate, G-CSF, Stem Cell Transplantation
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 13, 2026, 2:46 PM EDT
Recruiting Not applicable Interventional

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

NCT03686709
View directory record Official record
Conditions
Hepatocellular Carcinoma, Radiation Exposure
Interventions
Post therapy PET/CT Imaging
Diagnostic Test
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 13, 2026, 2:46 PM EDT
Not yet recruiting Phase 1 Interventional

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT07682649
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Other · Drug + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 1Phase 2 Interventional

A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects

NCT00162045
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Technetium Tc99m Sestamibi
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
4 Years to 16 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
Miami, Florida • Honolulu, Hawaii • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 13, 2026, 2:46 PM EDT
Withdrawn No phase listed Observational

A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)

NCT01085162
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
BMS747158
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 13, 2026, 2:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition

NCT00968097
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
123-I MNI-340
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)

NCT01778218
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose
Radiation
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

NCT06122610
View directory record Official record
Conditions
Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor
Interventions
Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate, 177Lu-Dotatate
Device · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

NCT00117819
View directory record Official record
Conditions
Parkinsonian Syndrome
Interventions
[123I]ß CIT and SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
22 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 13, 2026, 2:46 PM EDT
Terminated Not applicable Interventional Results available

Half-Dose Radiopharmaceutical in Wide Beam Reconstruction

NCT01499654
View directory record Official record
Conditions
Myocardial Infarction, Ischemic Heart Disease
Interventions
Half-dose of the Tc99-m sestamibi (Cardiolite)
Drug
Lead sponsor
Edwin Wu
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 13, 2026, 2:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Myocardial Ischemia Detection for Early Identification of Patients With Ischemic Chest Pain

NCT02055443
View directory record Official record
Conditions
Cardiac Ischemia, Chest Pain, Shortness of Breath
Interventions
12-lead holter monitor application
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 13, 2026, 2:46 PM EDT
Completed No phase listed Observational Results available

Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)

NCT01952678
View directory record Official record
Conditions
Essential Tremor, Parkinson's Disease
Interventions
DaTscan™ - Non-Caucasian Participants, DaTscan™ - Caucasian Participants
Other
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 13, 2026, 2:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

NCT02865434
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection), Whole body planar SPECT imaging (15 Minutes post-injection), Whole body planar SPECT imaging (60 Minutes post-injection), Whole body planar SPECT imaging (180 Minutes post-injection), Whole body planar SPECT imaging (18-20 Hours post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after injection), Blood Collection for PK Testing (15 minutes post injection), Blood Collection for PK Testing (60 minutes post injection), Blood Collection for PK Testing (180 minutes post injection), Blood Collection for PK Testing (18-20 hours post injection), Planar Image with both Hands in Field of View
Drug · Procedure
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 13, 2026, 2:46 PM EDT